TEL AVIV, Israel
July 5, 2012
InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced today that
, Chief Financial Officer, will present at the 7
Annual JMP Securities Healthcare Conference on
New York City
- Date: Thursday, July 12, 2012
- Time: 3 PM
- Location: Chelsea Room, The Peninsula Hotel, 700 5th Avenue, New York, NY.
About the JMP Securities Healthcare Conference
Annual JMP Securities Healthcare Conference will take place at the Peninsula Hotel in
. This institutional investor forum will feature more than 100 publicly traded and privately held companies in the life sciences field.
JMP Securities is a full-service investment bank that provides equity research, institutional brokerage and investment banking services to growth companies and their investors. The firm specializes in four broad growth industries: Technology, Healthcare, Financial Services and Real Estate. JMP's research department covers primarily small and mid-cap public companies
Attendance at this event is restricted to clients of JMP Securities. For full event details and registration information, please click here:
About InspireMD, Inc.
InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard
. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".
MGuard™ combines a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that is integrated with the stent. The MGuard™ is designed to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard™ is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC).